Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients: Data from the Swiss registry AMIS-Plus

Swiss Medical Weekly

Volumn 142, Issue MAY, 2012, Pages

  Stauffer, Jean Christophe ^a   Goy, Jean Jacques ^a   Duvoisin, Nicole ^a   Radovanovic, Dragana ^a   Rickli, Hans ^a   Erne, Paul ^a  

^a NONE

Author keywords

Acute coronary syndrome; Clopidogrel; STEMI

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DEATH; DRUG EFFECT; FEMALE; HEART DEATH; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION; CONFIDENCE INTERVAL; DRUG COMBINATION; ELECTROCARDIOGRAPHY; HEART CATHETERIZATION; HEART INFARCTION; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGISTER; RISK; STATISTICAL MODEL; SWITZERLAND; TIME;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HOSPITAL MORTALITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; REGISTRIES; SWITZERLAND; TICLOPIDINE; TIME FACTORS; YOUNG ADULT;

EID: 84863448138     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2012.13573     Document Type: Article

References (16)

1. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011:32:2999-3054.
2. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J. 2008; 29:2909-45.
3. Husted S, Evidence-based prescribing and adherence to antiplatelet therapy - how much difference do they make to patients with atherothrombosis? Int J Cardiol. 2009; 134:150-9.
4. Alexander D, Ou FS, Roe MT, et al. Use of and in hospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: Results from Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). Am Heart J. 2008; 156:606-12.
5. Silber S, Albertsson P, Avilés FF, et al. Guidelines for percutaneous coronary interventions. Eur Heart J. 2005; 26:804-47. (Pubitemid 40547082)
6. Jackevicius CA, Tu JV, Demers V, et al. Cardiovascular outcomes after a change in prescription policy for clopidogrel. N Engl J Med. 2008; 359:1802-10.
7. The CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-500.
8. Outcome of patients with acute coronary syndrome in hospitals of different sizes. A report from the AMIS Plus Registry. Radovanovic D, Urban P, Simon R, Schmidli M, Maggiorini M, Rickli H, Stauffer JC, Seifert B, Gutzwiller F, Erne P; AMIS Plus Investigators. Swiss Med Wkly. 2010;140(21-22):314-22.
9. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet. 2001;358:527-33. (Pubitemid 32772726)
10. Sean C. Beinart, Paul Kolm, Emir Veledar, Zefeng Zhang, Elizabeth M. Mahoney, Olivier Bouin, et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. J Am Coll Cardiol. 2005;46:761-9.
11. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med. 2001;345:494-502. (Pubitemid 32758501)
12. Steinhubl SR, Berger PB, Mann 3rd JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-20. (Pubitemid 35340537)
13. Banihashemi B, Goodman SG, Yan RT,Welsh RC, Mehta SR, Montalescot G, et al.; Global Registry of Acute Coronary Events (GRACE/GRACE(2)) Investigators. Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience. Am Heart J. 2009;158:917-24.
14. Montalescot G, Dallongeville J, van Belle E, et al. STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). Eur Heart J. 2007;28:1409-17. (Pubitemid 47343817)
15. Dangas G, Mehran R, Guagliumi G, Caixeta A, Witzenbichler B, Aoki J, et al.; HORIZONS-AMI Trial Investigators. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONSAMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol. 2009;54:1438-46.
16. Bland JM and Altman DG. Statistics Notes: The odds ratio. BMJ. 2000;320:1468.